JP2013529619A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013529619A5 JP2013529619A5 JP2013515902A JP2013515902A JP2013529619A5 JP 2013529619 A5 JP2013529619 A5 JP 2013529619A5 JP 2013515902 A JP2013515902 A JP 2013515902A JP 2013515902 A JP2013515902 A JP 2013515902A JP 2013529619 A5 JP2013529619 A5 JP 2013529619A5
- Authority
- JP
- Japan
- Prior art keywords
- chloropyrimidin
- thiazol
- tert
- butyl
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- XHYXSIFQGLTLTM-UHFFFAOYSA-N 3-[2-tert-butyl-5-(2-chloropyrimidin-4-yl)-1,3-thiazol-4-yl]-2-fluoroaniline Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(N)C=CC=2)F)=C1C1=CC=NC(Cl)=N1 XHYXSIFQGLTLTM-UHFFFAOYSA-N 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- NDJDJAPJBPWWIV-UHFFFAOYSA-N n-[3-[2-tert-butyl-5-(2-chloropyrimidin-4-yl)-1,3-thiazol-4-yl]-2-fluorophenyl]methanesulfonamide Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(C)(=O)=O)C=CC=2)F)=C1C1=CC=NC(Cl)=N1 NDJDJAPJBPWWIV-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000006103 sulfonylation Effects 0.000 description 1
- 238000005694 sulfonylation reaction Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35860310P | 2010-06-25 | 2010-06-25 | |
| US61/358,603 | 2010-06-25 | ||
| US36853410P | 2010-07-28 | 2010-07-28 | |
| US61/368,534 | 2010-07-28 | ||
| PCT/EP2011/060561 WO2011161216A1 (en) | 2010-06-25 | 2011-06-23 | Heteroaryl compounds and compositions as protein kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013529619A JP2013529619A (ja) | 2013-07-22 |
| JP2013529619A5 true JP2013529619A5 (enExample) | 2014-07-24 |
Family
ID=44280749
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013515902A Pending JP2013529619A (ja) | 2010-06-25 | 2011-06-23 | タンパク質キナーゼ阻害剤としてのヘテロアリール化合物および組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20130096149A1 (enExample) |
| EP (1) | EP2585454A1 (enExample) |
| JP (1) | JP2013529619A (enExample) |
| KR (2) | KR20130048293A (enExample) |
| CN (1) | CN103080107A (enExample) |
| AU (1) | AU2011268906A1 (enExample) |
| BR (1) | BR112012032884A2 (enExample) |
| CA (1) | CA2803055A1 (enExample) |
| EA (1) | EA201201676A1 (enExample) |
| MX (1) | MX2012015100A (enExample) |
| WO (1) | WO2011161216A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9199979B2 (en) * | 2011-02-24 | 2015-12-01 | Nerviano Medical Sciences S.R.L. | Thiazolylphenyl-benzenesulfonamido derivatives as kinase inhibitors |
| US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| WO2014172639A1 (en) * | 2013-04-19 | 2014-10-23 | Ruga Corporation | Raf kinase inhibitors |
| UY36294A (es) | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
| CN109715163B (zh) | 2016-09-19 | 2022-11-22 | 诺华股份有限公司 | 包含raf抑制剂和erk抑制剂的治疗组合 |
| EP3515909A1 (en) | 2016-09-23 | 2019-07-31 | Cellipse | Lim kinase inhibitors, pharmaceutical composition and method of use in limk-mediated diseases |
| WO2018203219A1 (en) | 2017-05-02 | 2018-11-08 | Novartis Ag | Combination therapy |
| WO2020124397A1 (en) * | 2018-12-19 | 2020-06-25 | Inventisbio Shanghai Ltd. | C-terminal src kinase inhibitors |
| EP4563150A3 (en) | 2019-05-13 | 2025-07-23 | Novartis AG | New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl) isonicotinamide as raf inhibitors for the treatment of cancer |
| CN114746419B (zh) * | 2019-12-05 | 2023-10-24 | 国家医疗保健研究所 | N-(3-(5-(嘧啶-4-基)噻唑-4-基)苯基)磺酰胺化合物及其用作braf抑制剂的用途 |
| CN111320548B (zh) * | 2020-04-24 | 2022-10-18 | 浦拉司科技（上海）有限责任公司 | 抗癌药物中间体2-氟-3-氨基苯甲酸甲酯的合成方法 |
| EP4281436A1 (en) * | 2021-01-20 | 2023-11-29 | Basf Se | Synthesis of polyfluorinated aryl and heteroaryl carboxamides |
| KR20240167846A (ko) | 2022-03-28 | 2024-11-28 | 니캉 테라퓨틱스 인코포레이티드 | 사이클린 의존적 키나제 2 억제제로서의 설폰아미도 유도체 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6358932B1 (en) | 1994-05-31 | 2002-03-19 | Isis Pharmaceticals, Inc. | Antisense oligonucleotide inhibition of raf gene expression |
| US6391636B1 (en) | 1994-05-31 | 2002-05-21 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of raf gene expression |
| US6037136A (en) | 1994-10-24 | 2000-03-14 | Cold Spring Harbor Laboratory | Interactions between RaF proto-oncogenes and CDC25 phosphatases, and uses related thereto |
| US5717100A (en) | 1995-10-06 | 1998-02-10 | Merck & Co., Inc. | Substituted imidazoles having anti-cancer and cytokine inhibitory activity |
| IL127210A0 (en) | 1996-05-23 | 1999-09-22 | Applied Research Systems | Compounds inhibiting the binding of raf-1 or 13-3-3 proteins to the beta-chain of il-2 pharmaceutical compositions containing them and their use |
| AR012634A1 (es) | 1997-05-02 | 2000-11-08 | Sugen Inc | Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion |
| US6187799B1 (en) | 1997-05-23 | 2001-02-13 | Onyx Pharmaceuticals | Inhibition of raf kinase activity using aryl ureas |
| GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
| US6022884A (en) | 1997-11-07 | 2000-02-08 | Amgen Inc. | Substituted pyridine compounds and methods of use |
| US6204467B1 (en) | 1998-03-24 | 2001-03-20 | Ford Global Technologies, Inc. | Method and apparatus for resistive welding |
| US7351834B1 (en) | 1999-01-13 | 2008-04-01 | Bayer Pharmaceuticals Corporation | ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| US6756410B2 (en) | 2000-08-30 | 2004-06-29 | Kamal D. Mehta | Induction of LDL receptor expression by extracellular-signal regulated kinase, ERK-1/2 |
| JP2003063993A (ja) * | 2001-06-11 | 2003-03-05 | Takeda Chem Ind Ltd | 医薬組成物 |
| SG2013013339A (en) | 2002-03-13 | 2014-12-30 | Array Biopharma Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
| TW200626610A (en) | 2004-10-13 | 2006-08-01 | Wyeth Corp | Analogs of 17-hydroxywortmannin as PI3K inhibitors |
| MX2007010401A (es) | 2005-02-25 | 2008-02-19 | Kudos Pharm Ltd | Derivados de 2,4-diamino-piridopirimidina y su uso como inhbidores de mtor. |
| EP1877388A2 (en) | 2005-02-25 | 2008-01-16 | Kudos Pharmaceuticals Ltd | Hydrazinomethyl, hydrazonomethyl and 5-membered heterocylic compounds which act as mtor inhibitors and their use as anti cancer agents |
| KR101464384B1 (ko) | 2005-11-22 | 2014-11-21 | 쿠도스 파마슈티칼스 리미티드 | ｍＴＯＲ 억제제로서 피리도피리미딘, 피라조피리미딘 및피리미도피리미딘 유도체 |
| KR20080083188A (ko) | 2006-01-11 | 2008-09-16 | 아스트라제네카 아베 | 모르폴리노 피리미딘 유도체 및 요법에서의 그 유도체의용도 |
| JP5227321B2 (ja) | 2006-08-23 | 2013-07-03 | クドス ファーマシューティカルズ リミテッド | Ｍｔｏｒ阻害剤としての２−メチルモルホリンピリド−、ピラゾ−及びピリミド−ピリミジン誘導体 |
| JP2010533729A (ja) * | 2007-07-17 | 2010-10-28 | プレキシコン，インコーポレーテッド | キナーゼ調節のための化合物と方法、及びそのための適応 |
| JP2011506454A (ja) * | 2007-12-13 | 2011-03-03 | グラクソスミスクライン エルエルシー | チアゾールおよびオキサゾールキナーゼ阻害薬 |
| UA103319C2 (en) * | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
| EP2324008B1 (en) * | 2008-07-24 | 2012-05-09 | Nerviano Medical Sciences S.R.L. | 3,4-diarylpyrazoles as protein kinase inhibitors |
| EP2498608A4 (en) * | 2009-11-10 | 2013-04-24 | Glaxosmithkline Llc | BENZOLSULFONAMIDE THIAZOL AND OXAZOLE COMPOUNDS |
-
2011
- 2011-06-23 BR BR112012032884A patent/BR112012032884A2/pt not_active IP Right Cessation
- 2011-06-23 CN CN201180040746XA patent/CN103080107A/zh active Pending
- 2011-06-23 US US13/805,793 patent/US20130096149A1/en not_active Abandoned
- 2011-06-23 KR KR1020137001935A patent/KR20130048293A/ko not_active Abandoned
- 2011-06-23 KR KR1020147024689A patent/KR20140117684A/ko not_active Withdrawn
- 2011-06-23 MX MX2012015100A patent/MX2012015100A/es not_active Application Discontinuation
- 2011-06-23 WO PCT/EP2011/060561 patent/WO2011161216A1/en not_active Ceased
- 2011-06-23 CA CA2803055A patent/CA2803055A1/en not_active Abandoned
- 2011-06-23 EA EA201201676A patent/EA201201676A1/ru unknown
- 2011-06-23 EP EP11728247.5A patent/EP2585454A1/en not_active Withdrawn
- 2011-06-23 AU AU2011268906A patent/AU2011268906A1/en not_active Abandoned
- 2011-06-23 JP JP2013515902A patent/JP2013529619A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010505891A5 (enExample) | ||
| JP2014138100A5 (enExample) | ||
| DK2683708T3 (da) | Faste former af 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidin-2,6-dion og farmaceutiske sammensætninger og anvendelser deraf | |
| SMT201600057B (it) | 3,5-diammino-6-cloro-n-(n-(4-(4-(2-(esil(2,3,4,5,6-pentaidrossiesil)ammino)etossi)fenil)butil)- carbammimidoil)pirazina-2-carbossammide | |
| JP2015522045A5 (enExample) | ||
| JP2013514381A5 (enExample) | ||
| LT3127540T (lt) | Tam tikri aminopiridinai, jų kompozicijos ir jų panaudojimo būdai | |
| JP2013540852A5 (enExample) | ||
| JP2014513036A5 (enExample) | ||
| JP2016508542A5 (enExample) | ||
| BR112015023218A2 (pt) | formas sólidas de 5- (halometil)furfural e métodos para preparar as mesmas | |
| JP2011527428A5 (enExample) | ||
| WO2017015433A3 (en) | Compound targeting il-23a and b-cell activating factor (baff) and uses thereof | |
| JP2014517802A5 (enExample) | ||
| CL2015001318A1 (es) | Compuestos derivados de pirazina, agonistas del receptor cb2; proceso de obtencion; composicion farmaceutica y el uso en el tratamiento de enfermedades tales como aterosclerosis, glaucoma, diabetes, entre otras. | |
| BR112017004673A2 (pt) | formas cristalinas de 2-(4-(4-etoxi-6-oxo-1,6-diidropiridin-3-ila)-2-fluorofenil)-n-(5-(1,1,1-trifluoro-2-metilpropan-2-il)isoxazol-3-il) acetamida | |
| EA201370149A1 (ru) | Антагонисты рецептора | |
| JP2014521346A5 (enExample) | ||
| JP2017092104A5 (enExample) | ||
| SMT201500069B (it) | Composizioni farmaceutiche comprendenti n-(4-(2-ammino-3-cloropiridin-4-ilossi)-3-fluorofenil)-4-etossi-l-(4-fluorofenil)-2-osso-1,2-diidropiridin-3-carbossammide | |
| UY33511A (es) | Procedimiento de obtención de la forma cristalina ii del febuxostat | |
| JP2010208011A5 (enExample) | ||
| JP2017518319A5 (enExample) | ||
| MX375758B (es) | Sales y polimorfos de un compuesto imidazopiridinil-aminopiridina sustituido. | |
| WO2011047390A3 (en) | Heterocyclic benzoxazole compositions as inhibitors of hepatitis c virus |